Syndax Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $72,788 | $64,864 | $68,481 | $45,871 |
Gross Profit | 69,580 | 62,231 | 70,053 | 43,771 |
EBITDA | -36,687 | -30,823 | -15,309 | -52,429 |
EBIT | -30,827 | -15,312 | -52,432 | |
Net Income | -49,363 | -42,673 | -68,014 | -60,715 |
Net Change In Cash | 72,788 | 64,864 | 68,481 | 45,871 |
Free Cash Flow | -30,312 | -50,345 | -69,544 | -70,666 |
Cash | 336,477 | 130,893 | 134,930 | 116,808 |
Basic Shares | 88,991 | 86,620 | 86,620 | 86,620 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $172,352 | $23,680 | $0 | $126,576 |
Gross Profit | 165,382 | 22,854 | -12 | -454 |
EBITDA | -251,631 | -313,821 | -209,140 | -151,724 |
EBIT | -251,637 | -313,829 | -209,152 | -151,757 |
Net Income | -285,422 | -318,758 | -209,360 | -143,749 |
Net Change In Cash | 172,352 | 23,680 | 0 | 126,576 |
Free Cash Flow | -323,167 | -274,903 | -160,601 | -133,900 |
Cash | 134,930 | 154,083 | 295,394 | 74,356 |
Basic Shares | 86,625 | 85,622 | 70,370 | 60,760 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.55 |
2026-03-31 | -$0.48 |
2025-12-31 | -$0.78 |
2025-09-30 | -$0.70 |